Drug Profile

TG 100115

Alternative Names: TG100-115

Latest Information Update: 17 Sep 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TargeGen
Class Cardiovascular therapies; Phenols; Pteridines; Small molecules
Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Asthma; Chronic obstructive pulmonary disease; Myocardial infarction

Most Recent Events

26 Jan 2011 CyDex Pharmaceuticals has been acquired by Ligand Pharmaceuticals
30 Jun 2010 Sanofi-aventis agrees to acquire TargeGen
04 Dec 2008 Pharmacodynamics and safety data from a preclinical trial in Asthma and chronic obstructive pulmonary disease released by TargeGen

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com